Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial
AbstractPurposePI3K/AKT pathway alterations are frequent in hormone receptor-positive (HR+) breast cancers. IPATunity130 Cohort B investigated ipatasertib –paclitaxel in PI3K pathway-mutant HR+ unresectable locally advanced/metastatic breast cancer (aBC).MethodsCohort B of the randomized, double-blind, placebo-controlled, phase 3 IPATunity130 trial enrolled patients with HR+  HER2-negativePIK3CA/AKT1/PTEN-altered measurable aBC who were considered inappropriate for endocrine-based therapy (demonstrated insensitivity to endocrine therapy or visceral crisis) and were candidates for taxane monotherapy. Pat...
Source: Breast Cancer Research and Treatment - December 3, 2021 Category: Cancer & Oncology Source Type: research

Studying the association between breast cancer and renal cell carcinoma
ConclusionOur findings suggest that BC patients are at higher risk of developing RCC and vice versa. BC tended to precede RCC, and patients frequently had personal histories of other malignancies and a family history of cancer, particularly, BC. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - December 2, 2021 Category: Cancer & Oncology Source Type: research

Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: benefits of physician selective testing
This study evaluated the clinical utility of EndoPredict ®, in terms of impact on adjuvant therapy recommendations and identification of parameters to guide selective application.MethodsPatients with ER-positive, HER2-negative, and early-stage invasive breast cancer were tested with EndoPredict ®. Two cohorts were recruited: one consecutively and another at clinical team discretion. Systemic treatment recommendations were recorded before and after EndoPredict® results were revealed to the multidisciplinary team.Results233 patients were recruited across five sites: 123 consecutive and 110 at clinical team discre...
Source: Breast Cancer Research and Treatment - December 1, 2021 Category: Cancer & Oncology Source Type: research

The impact of the COVID-19 pandemic on perceived access to health care and preferences for health care provision in individuals (being) treated for breast cancer
ConclusionPerceived access to health care has improved substantially throughout the pandemic. Digital care is well received by patients (being) treated for breast cancer. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - December 1, 2021 Category: Cancer & Oncology Source Type: research

Impact of rapid genetic testing for BRCA1 and BRCA2 at time of breast cancer diagnosis on psychosocial functioning
ConclusionFor women who have RGT forBRCA1 andBRCA2 at the time of breast cancer diagnosis, identifying aBRCA1 orBRCA2 mutation does not impair psychosocial functioning in the short or long term. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - November 30, 2021 Category: Cancer & Oncology Source Type: research

Breast cancer vaccines for treatment and prevention
AbstractBreast cancer is immunogenic and a variety of vaccines have been designed to boost immunity directed against the disease. The components of a breast cancer vaccine, the antigen, the delivery system, and the adjuvant, can have a significant impact on vaccine immunogenicity. There have been numerous immunogenic proteins identified in all subtypes of breast cancer. The majority of these antigens are weakly immunogenic nonmutated tumor-associated proteins. Mutated proteins and neoantigen epitopes are found only in a small minority of patients and are enriched in the triple negative subtype. Several vaccines have advanc...
Source: Breast Cancer Research and Treatment - November 30, 2021 Category: Cancer & Oncology Source Type: research

A case-case analysis of women with breast cancer: predictors of interval vs screen-detected cancer
We examined the association between high BCSC risk (defined as the top 2.5% by age) and breast cancers presenting as int erval cancers.MethodsWe conducted a case-case analysis among women with breast cancer in which we compared the mode of detection and tumor characteristics of patients in the top 2.5% BCSC risk by age with age-matched (1:2) patients in the lower 97.5% risk. We constructed logistic regression models to estimate the odds ratio (OR) of presenting with interval cancers, and poor prognosis tumor features, between women from the top 2.5% and bottom 97.5% of BCSC risk.ResultsOur analysis included 113 breast canc...
Source: Breast Cancer Research and Treatment - November 29, 2021 Category: Cancer & Oncology Source Type: research

Average duration of prior treatment lines predicts clinical benefit to eribulin chemotherapy in patients with metastatic breast cancer
AbstractPurposeThe aim of this study was to identify factors associated with progression-free survival (PFS) and overall survival (OS) in patients with metastatic breast cancer (MBC) treated with eribulin in a real-world setting, to improve information provision in those considering treatment.MethodsPatients treated with eribulin for MBC at The Christie NHS Foundation Trust, Manchester, UK, between August 2011 and December 2018 were included (n = 439). Data were collected by retrospective review of medical records and electronic prescribing systems. Factors such as biological subtype, distant recurrence-free ...
Source: Breast Cancer Research and Treatment - November 29, 2021 Category: Cancer & Oncology Source Type: research

Factors related to patient-reported cosmetic outcome after breast-conserving therapy for breast cancer
ConclusionIn the present study, a variety of factors is explored. However, a radiotherapy boost was the only factor that was independently associated with a poor cosmetic outcome after BCT. This finding can be used for counselling in daily clinical practice. Creation of a prediction model will require further investigation. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - November 29, 2021 Category: Cancer & Oncology Source Type: research

Predicting the clinical outcomes and benefit from letrozole after 5  years of treatment with aromatase inhibitors for early breast cancer: analysis from CCTG MA.17R
ConclusionA nomogram with good performance may be used to accurately predict distant recurrence risk and also benefits with extended treatment after 5  years of aromatase inhibitors. Future independent validation of the proposed nomogram is warranted.Trial registration numberNCT00754845 (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - November 26, 2021 Category: Cancer & Oncology Source Type: research

Circulating lipids and breast cancer prognosis in the Malm ö diet and cancer study
ConclusionHigh pre-diagnostic levels of Apo B were associated with an increased risk of recurrence among breast cancer patients. Circulating Apo A-1 was not associated with breast cancer outcomes. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - November 25, 2021 Category: Cancer & Oncology Source Type: research

Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis
ConclusionOur results suggest that the site of metastasis is associated with prognosis in HER2-positive breast cancer, highlighted by the poor prognosis of liver metastases. Furthermore, liver metastases were associated with adverse tumour immune cell profiles. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - November 24, 2021 Category: Cancer & Oncology Source Type: research

Is the oncotype DX test useful in elderly breast cancer patients: a subgroup analysis of real-life Italian PONDx study
Conclusions21-gene test may be helpful even in a relatively low-risk group as elderly patients and may avoid the toxicity of adjuvant chemotherapy in a significant amount. If the Oncotype DX test is currently adopted on a large scale among the elderly and may impact the general prognosis of elderly BC patients, it is challenging and still unproven. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - November 24, 2021 Category: Cancer & Oncology Source Type: research

Dietary supplement use and documentation in a breast cancer survivorship clinic
Conclusion90% of the breast cancer survivors in our study were taking dietary supplements for a variety of reasons. None had an accurate list in the EMR. We strongly recommend more attention to accurate and easily accessed vitamin and supplement recording by providers. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - November 24, 2021 Category: Cancer & Oncology Source Type: research

qRT-PCR-based DNA homologous recombination-associated 4-gene score predicts pathologic complete response to platinum-based neoadjuvant chemotherapy in triple-negative breast cancer
AbstractPurposeCumulative evidence suggests that the addition of platinum agents as neoadjuvant chemotherapy (NACT) could improve the pathologic complete response (pCR) rate in triple-negative breast cancer (TNBC). We aimed to develop a DNA homologous recombination (HR)-associated gene expression score to predict tumor sensitivity to platinum-based NACT in TNBC.MethodsA retrospective cohort of 127 patients who were diagnosed with TNBC and received platinum-based NACT in Fudan University Shanghai Cancer Center from 2012 to 2017 was included in this study. Using quantitative reverse transcription-polymerase chain reaction (q...
Source: Breast Cancer Research and Treatment - November 19, 2021 Category: Cancer & Oncology Source Type: research

Classes of therapeutics to amplify the immune response
ConclusionMechanistic considerations should inform biomarker development and patient selection for therapeutic combinations of drugs to combine with immune-checkpoint inhibitors. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - November 17, 2021 Category: Cancer & Oncology Source Type: research

Does definitive local therapy have a role in select HER2+  de novo metastatic breast cancer patients treated with dual anti-HER2 blockade?
ConclusionIn a group of HER2+  dnMBC patients receiving systemic treatment in the era of dual antibody therapy, patients who underwent surgery had a superior 3-year survival rate than those who did not. There may be a role for a prospective trial in HER2+ dnMBC patients with an excellent response to dual HER2 blockade to inv estigate the contribution of curative intent local therapy to the primary tumor compared to systemic therapy alone. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - November 17, 2021 Category: Cancer & Oncology Source Type: research

Comparison of risk assessment in 1652 early ER positive, HER2 negative breast cancer in a real-world data set: classical pathological parameters vs. 12-gene molecular assay (EndoPredict)
AbstractBackgroundRisk assessment on the molecular level is important in predictive pathology to determine the risk of metastatic disease for ERpos, HER2neg breast cancer. The gene expression test EndoPredict (EP) was trained and validated for prediction of a 10-year risk of distant recurrence to support therapy decisions regarding endocrine therapy alone or in combination with chemotherapy. The EP test provides the 12-gene Molecular Score (MS) and the EPclin-Score (EPclin), which combines the molecular score with tumor size and nodal status. In this project we investigated the correlation of 12-gene MS and EPclin scores w...
Source: Breast Cancer Research and Treatment - November 16, 2021 Category: Cancer & Oncology Source Type: research

A catalog of curated breast cancer genes
ConclusionsWe have built an online interactive catalog of curated breast cancer genes (https://cbcg.dk). This will expedite clinical diagnostics and support the ongoing efforts in managing breast cancer etiology. Moreover, the database will serve as an essential repository when designing new breast cancer multigene panels. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - November 10, 2021 Category: Cancer & Oncology Source Type: research

Breast cancer outcomes following immediate breast reconstruction with implants versus autologous flaps: a propensity score-matched study
ConclusionIn this propensity score-matched analysis of oncologic outcomes in patients with primary breast cancer who underwent immediate breast reconstruction with nipple-/skin-sparing mastectomy, no significant differences were observed between the IBR and AFR groups. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - November 10, 2021 Category: Cancer & Oncology Source Type: research

Supervised machine learning model to predict oncotype DX risk category in patients over age 50
ConclusionOur model was highly specific for identifying eligible patients aged over 50  years for whom chemotherapy can be omitted. Following external validation, it may be used to triage patients for RS testing, if predicted to be high risk, in resource-limited settings. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - November 9, 2021 Category: Cancer & Oncology Source Type: research

Correction to: Germline variants in hereditary breast cancer genes are associated with early age at diagnosis and family history in Guatemalan breast cancer
(Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - November 9, 2021 Category: Cancer & Oncology Source Type: research

Patient-reported treatment toxicity and adverse events in Black and White women receiving chemotherapy for early breast cancer
ConclusionExcept for lymphedema and peripheral neuropathy, Black and White patients reported similar symptom severity during adjuvant chemotherapy. Dose reductions in Black patients were more common for non-anthracycline regimens. In this sample, there were minimal differences in patient-reported symptoms and other adverse outcomes in Black versus White patients. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - November 5, 2021 Category: Cancer & Oncology Source Type: research

Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis
ConclusionUse of HRT was associated with a detrimental prognostic effect in BC survivors, particularly in those with hormone receptor-positive disease. Alternative interventions to mitigate menopause-related symptoms should be proposed. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - November 3, 2021 Category: Cancer & Oncology Source Type: research

Breast cancer immune microenvironment: from pre-clinical models to clinical therapies
AbstractThe breast cancer tumour microenvironment (BC-TME) is characterized by significant cellular and spatial heterogeneity that has important clinical implications and can affect response to therapy. There is a growing need to develop methods that reliably quantify and characterize the BC-TME and model its composition and functions in experimental systems, in the hope of developing new treatments for patients. In this review, we examine the role of immune-activating cells (including tumour-infiltrating lymphocytes and natural killer cells) and immune inhibitory cells (including T regulatory cells, tumour-associated macr...
Source: Breast Cancer Research and Treatment - November 3, 2021 Category: Cancer & Oncology Source Type: research

The frequency and clinical significance of DNA polymerase beta (POL β) expression in breast ductal carcinoma in situ (DCIS)
ConclusionLoss of POL β in DCIS is associated with aggressive behaviour and it can predict recurrence. POLβ expression in DCIS provides an additional feature for patients’ risk stratification for personalised therapy. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - October 31, 2021 Category: Cancer & Oncology Source Type: research

Multilevel predictors of guideline concordant needle biopsy use for non-metastatic breast cancer
ConclusionThis study suggests a need to account for sociodemographic factors including rurality as predictors of utilization of evidence-based diagnostic testing, such as needle biopsy. Addressing inequities in breast cancer diagnosis quality may help improve breast cancer outcomes in underserved patients. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - October 31, 2021 Category: Cancer & Oncology Source Type: research

Brief relaxation training is associated with long-term endocrine therapy adherence among women with breast cancer: post hoc analysis of a randomized controlled trial
ConclusionWomen receiving relaxation training were less likely to (1) forget to take their AET and (2) intentionally miss doses of AET in the long term compared to women receiving health education or CBT. This is evidence for the need of randomized trials that aim to improve adherence by incorporating theoretically based behavioral change techniques.Trial registration and datesTrial 2R01-CA-064710 was registered March 26, 2006. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - October 31, 2021 Category: Cancer & Oncology Source Type: research

Hormone receptor-positive breast cancer and black race: does sex matter?
The objective of this study is to examine differences in presentation, treatment, and mortality between Black MBC and FBC.MethodsThe National Cancer Database was queried for all Black MBC and FBC patients, ages 18 –90, with hormone receptor-positive breast cancer diagnosed between 2010 and 2016. Hormone receptor positivity was defined as estrogen receptor-positive, progesterone-positive and HER 2-negative cancer. Sociodemographic and clinical variables were compared between MBC and FBC patients on bivariabl e analysis. After propensity score matching, overall survival was evaluated using the log-rank test and Cox pro...
Source: Breast Cancer Research and Treatment - October 31, 2021 Category: Cancer & Oncology Source Type: research

Investigating the role of endogenous estrogens, hormone replacement therapy, and blockade of estrogen receptor- α activity on breast metabolic signaling
ConclusionAlterations in estrogen bioavailability are associated with changes in the mammary tissue metabolome, particularly in glucose and fatty acid metabolism. Changes in these pathways may represent a bioenergetic shift in gland metabolism at menopause that may affect breast cancer risk. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - October 31, 2021 Category: Cancer & Oncology Source Type: research

Effects of exercise in breast cancer patients: implications of the trials within cohorts (TwiCs) design in the UMBRELLA Fit trial
ConclusionTwiCs gave insight into exercise intervention acceptance: about half of inactive breast cancer survivors accepted the offer and increased physical activity levels. The offer resulted in no improvement on QoL, and a small beneficial effect on physical fatigue.Trial registrationNetherlands Trial Register (NTR5482/NL.52062.041.15), date of registration: December 07, 2015. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - October 31, 2021 Category: Cancer & Oncology Source Type: research

Turning scientific serendipity into discoveries in breast cancer research and treatment: a tale of PhD students and a 50-year roaming tamoxifen team
This article follows the unanticipated discoveries when PhD students “get the wrong answer.” The secret of success of my six Tamoxifen Teams was their technical excellence to create models, to decipher mechanisms, that drove the development of new medicines.Summary of advancesDiscoveries are listed that either changed women ’s health or allowed an understanding of originally opaque mechanisms of action of potential therapies. These advances in women’s health were supported entirely by government-sponsored peer-reviewed funding and major philanthropy from the Lynn Sage Breast Cancer Foundation, the A...
Source: Breast Cancer Research and Treatment - October 31, 2021 Category: Cancer & Oncology Source Type: research

Breast cancer resistance mechanisms: challenges to immunotherapy
ConclusionsThe breast cancer immune TME is complex and the mechanisms driving resistance to ICB are multifaceted. Continued study in both preclinical models and clinical trials should help elucidate these mechanisms so they can be targeted to benefit more breast cancer patients. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - October 31, 2021 Category: Cancer & Oncology Source Type: research

HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer
ConclusionOur data does not support HER2-low as a biologically distinct BC subtype, with no prognostic value on survival outcomes and no predictive effect for pCR after conventional NACT. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - October 31, 2021 Category: Cancer & Oncology Source Type: research

Cholesterol lowering drug use and breast cancer survival: the Multiethnic Cohort Study
ConclusionThese findings demonstrate an improved survival associated with CLD use prior to diagnosis in a multiethnic population of women with BC. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - October 31, 2021 Category: Cancer & Oncology Source Type: research

Myosteatosis at diagnosis is adversely associated with 2-year survival in women with estrogen receptor-negative metastatic breast cancer
AbstractPurposeTo examine the relationship between skeletal muscle (SM) and cancer-specific outcomes for women with estrogen receptor-negative (ER −) metastatic breast cancer (MBC).MethodsFor this retrospective cohort, females ( ≥ 18 years) with histologically confirmed ER− MBC and computerized tomography (CT) imaging were screened. Demographic, anthropometric, and clinical data were collected uniformly from the electronic medical record. CT images inclusive of the third lumbar region (L3) at diagnosis, 6 and 12 m onths, were used to classify sarcopenia (≤ 41 cm2/m2) and myosteatosis (
Source: Breast Cancer Research and Treatment - October 31, 2021 Category: Cancer & Oncology Source Type: research

Cardiac risk stratification of breast cancer patients in a cardio-oncology clinic
ConclusionOur study provides insight into referral practices, interventions, and outcomes at a cardio-oncology clinic. Furthermore, breast cancer patients continue to have high rates of HF. These findings suggest a need to shift referral practices upstream for a pre-chemotherapy evaluation to optimize cardiovascular health. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - October 31, 2021 Category: Cancer & Oncology Source Type: research

A randomized controlled trial of metformin in women with components of metabolic syndrome: intervention feasibility and effects on adiposity and breast density
AbstractPurposeObesity is a known risk factor for post-menopausal breast cancer and may increase risk for triple negative breast cancer in premenopausal women. Intervention strategies are clearly needed to reduce obesity-associated breast cancer risk.MethodsWe conducted a Phase II double-blind, randomized, placebo-controlled trial of metformin in overweight/obese premenopausal women with components of metabolic syndrome to assess the potential of metformin for primary breast cancer prevention. Eligible participants were randomized to receive metformin (850  mg BID,n = 76) or placebo (n = 75...
Source: Breast Cancer Research and Treatment - October 31, 2021 Category: Cancer & Oncology Source Type: research

Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9)
AbstractPurposeThe most appropriate therapy for HR  + /HER2-positive (HER2 +) advanced breast cancer (ABC) is a matter of debate. Co-targeting of both receptors represents an attractive strategy to overcome the cross-talk between them.MethodsThe HERMIONE 9 is an observational retrospective multicentric study which aimed to describe the clinical outcome of patients with HR  + /HER2 + ABC who received the combination of Fulvestrant (F) and Trastuzumab (T) as part of their routine treatment at 10 Italian Institutions.ResultsEighty-seven patients were included. Median age was 63...
Source: Breast Cancer Research and Treatment - October 31, 2021 Category: Cancer & Oncology Source Type: research

Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody –drug conjugates and bispecific antibodies
AbstractBreast cancer has historically been considered a non-immunogenic tumor. Multiple studies over the last 10 –15 years have demonstrated that a small subset of breast cancers is immune-activated, with PD-L1 expression and/or TILs in the tumor microenvironment. The PD-1 inhibitor pembrolizumab in combination with chemotherapy is now approved by the US FDA for the first-line treatment of metastatic PD-L1  + triple negative breast cancer, and the PD-L1 inhibitor atezolizumab has also demonstrated clinical activity. The median progression-free survival for pembrolizumab or atezolizumab combined wi...
Source: Breast Cancer Research and Treatment - October 30, 2021 Category: Cancer & Oncology Source Type: research

Emerging immunotherapeutic strategies for the treatment of breast cancer
AbstractImmunotherapy has resulted in unprecedented gains in long-term outcomes for many cancer types and has revolutionized the treatment landscape of solid tumor oncology. Checkpoint inhibition in combination with chemotherapy has proven to be effective for the treatment of a subset of advanced triple-negative breast cancer in the first-line setting. This initial success is likely just the tip of the iceberg as there is much that remains unknown about how to best harness the immune system as a therapeutic strategy in all breast cancer subtypes. Therefore, numerous ongoing studies are currently underway to evaluate the sa...
Source: Breast Cancer Research and Treatment - October 30, 2021 Category: Cancer & Oncology Source Type: research

Current advances in immune checkpoint inhibitor combinations with radiation therapy or cryotherapy for breast cancer
ConclusionRT and cryotherapy are local therapies that can be integrated safely with ICI and has shown promise in early trials. Randomized phase II studies testing both of these approaches, such as P-RAD (NCT04443348) and ipilimumab/nivolumab/cryoablation for TNBC (NCT03546686) are current enrolling. The results of these studies are paramount as they will provide long term data on the safety and efficacy of these regimens. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - October 29, 2021 Category: Cancer & Oncology Source Type: research

The 70-gene signature test as a prognostic and predictive biomarker in patients with invasive lobular breast cancer
The objective of this study is to evaluate the 70-gene signature test (ST) as a prognostic and predictive tool for ILC using a national cancer database.MethodsWe identified patients diagnosed with stage I –III ER-positive ILC from 2004 to 2016 using the National Cancer Database. All patients underwent 70-gene ST testing. We used the Kaplan–Meier method and Cox proportional hazard analyses to determine overall survival based on genomic risk classification. We also determined the benefit of adjuvan t chemotherapy for patients with high-genomic risk ILC based on 70-gene ST testing.ResultsWe identified 2610 patient...
Source: Breast Cancer Research and Treatment - October 29, 2021 Category: Cancer & Oncology Source Type: research

Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics
ConclusionsThese data, in total, demonstrate that trastuzumab, and by extension T-DM1, do not bind rat or mouse neu, underscoring the importance of species selection for safety studies investigating trastuzumab or trastuzumab-based therapeutics. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - October 27, 2021 Category: Cancer & Oncology Source Type: research

Evaluating anthracycline  + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study
AbstractPurposeAdjuvant chemotherapy reduces recurrence in early-stage triple-negative breast cancer (TNBC). However, data are lacking evaluating anthracycline  + taxane (ATAX) versus taxane-based (TAX) chemotherapy in older women with node-negative TNBC, as they are often excluded from trials. The purpose of this study was to evaluate the effect of adjuvant ATAX versus TAX on cancer-specific (CSS) and overall survival (OS) in older patients with node- negative TNBC.Patients and methodsUsing the SEER-Medicare database, we selected patients aged  ≥ 66 years diagnosed with Stage T1-4N0M0 T...
Source: Breast Cancer Research and Treatment - October 27, 2021 Category: Cancer & Oncology Source Type: research

KIF21A regulates breast cancer aggressiveness and is prognostic of patient survival and tumor recurrence
ConclusionThe data demonstrates that KIF21A is an important regulator of breast cancer aggressiveness and may be useful in refining prognostication of this malignant disease. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - October 26, 2021 Category: Cancer & Oncology Source Type: research

Vasomotor symptoms in midlife women with incident breast cancer: pink SWAN
ConclusionsPatterns of prevalent VMS reporting differed significantly between cases and controls, particularly post diagnosis, the latter only partially explained by tamoxifen use among cases. Risk factors for VMS largely did not differ between cases and controls. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - October 25, 2021 Category: Cancer & Oncology Source Type: research

Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer
ConclusionsPFS under first ET appears identical whether prescribed before or after chemotherapy. These data suggest chemotherapy does not promote endocrine resistance. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - October 23, 2021 Category: Cancer & Oncology Source Type: research

Elevated magnetic resonance imaging measures of adipose tissue deposition in women with breast cancer treatment-related lymphedema
AbstractPurposeBreast cancer treatment-related lymphedema (BCRL) is a common co-morbidity of breast cancer therapies, yet factors that contribute to BCRL progression remain incompletely characterized. We investigated whether magnetic resonance imaging (MRI) measures of subcutaneous adipose tissue were uniquely elevated in women with BCRL.MethodsMRI at 3.0  T of upper extremity and torso anatomy, fat and muscle tissue composition, andT2 relaxometry were applied in left and right axillae of healthy control (n = 24) and symptomatic BCRL (n = 22) participants to test the primary hypothesis that...
Source: Breast Cancer Research and Treatment - October 23, 2021 Category: Cancer & Oncology Source Type: research

Preoperative MRI in breast cancer: effect of breast density on biopsy rate and yield
ConclusionFor women with dense breasts, preoperative MRI was associated with much higher biopsy rates, without concomitant higher cancer detection. Preoperative MRI may be considered for some women, but selecting women based on breast density is not supported by evidence.Trial registrationClinicalTrials.gov: NCT02980848; registered 2017. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - October 22, 2021 Category: Cancer & Oncology Source Type: research